发明授权
- 专利标题: Bivalent thrombin inhibitors
- 专利标题(中): 二价凝血酶抑制剂
-
申请号: US636698申请日: 1996-06-28
-
公开(公告)号: US6127337A公开(公告)日: 2000-10-03
- 发明人: Yasuo Konishi , Zbigniew Szewczuk , Yuko Tsuda
- 申请人: Yasuo Konishi , Zbigniew Szewczuk , Yuko Tsuda
- 申请人地址: CAX Ottawa
- 专利权人: National Research Council of Canada
- 当前专利权人: National Research Council of Canada
- 当前专利权人地址: CAX Ottawa
- 优先权: GBX9321951 19931025; GBX9412707 19940624
- 主分类号: A61K38/00
- IPC分类号: A61K38/00 ; C07K14/815 ; A61K38/03 ; C07K7/00
摘要:
Hirudin is the most potent and specific thrombin inhibitor and is derived from the medicinal leech. It is reported to inhibit thrombin with an equilibrium dissociation constant (K.sub.i) value of 2.2.times.10.sup.-14 M. synthetic thrombin inhibitors have been designed based on the hirudin sequence but with a dramatically reduced size. The bulky active site inhibitor segment, hirudin.sup.1-48, has been substituted by small non-substrate type active site inhibitors of thrombin, e.g., dansyl-Arg-(D-pipecolic acid). The linker segment has also been modified using a combination of .omega.-amino acids to reduce the molecular weight but retaining sufficient length to span the two principal binding domains. Among the inhibitors designed, dansyl-Arg-(D-pipecolic acid)-(12-aminododecanoic acid)-4-aminobutyric acid)-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-(L-.beta.-cyclohexylalamine)-(D-Glu)-OH (SEQ ID NO:45) showed the highest affinity and displays a competitive-type inhibition. The incorporation of the non-substrate type active site inhibitor segment and the linker of .omega.-amino acids into the bivalent thrombin inhibitors not only improved in vitro thrombin inhibitory activity to the pM level, overcame proteolytic susceptibility at the level of the "normal" scissile bond and confered high in vivo activity.
公开/授权文献
- US5050624A Disposable eye makeup shield 公开/授权日:1991-09-24